25 Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Subjects with Diabetes and Chronic Kidney Disease

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2020.02.027 ◽

2020 ◽

Vol 75 (4) ◽

pp. 542-543

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Open Label Study ◽

Download Full-text

A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis

Nephron ◽

10.1159/000508100 ◽

2020 ◽

Vol 144 (8) ◽

pp. 372-382 ◽

Author(s):

Tadao Akizawa ◽

Yusuke Yamaguchi ◽

Tetsuro Otsuka ◽

Michael Reusch

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Download Full-text

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan

Therapeutic Apheresis and Dialysis ◽

10.1111/1744-9987.13611 ◽

2020 ◽

Author(s):

Masaomi Nangaku ◽

Kazuoki Kondo ◽

Souichirou Takabe ◽

Kiichiro Ueta ◽

Genki Kaneko ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Peritoneal Dialysis ◽

Kidney Disease ◽

Phase 3 ◽

Open Label Study ◽

Download Full-text

The evaluation of denosumab safety in patients with chronic kidney disease: An open-label study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e20649 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e20649-e20649

Author(s):

Geoffrey Block ◽

Ogo Egbuna ◽

Steven Zeig ◽

Pablo E. Pergola ◽

Bhupinder Singh ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Open Label Study ◽

Download Full-text

15 REDUX: A Multicenter, Open-label Study of DM199 (Recombinant Human Tissue Kallikrein-1) in Patients With Stage II or III Chronic Kidney Disease

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2021.02.020 ◽

2021 ◽

Vol 77 (4) ◽

pp. 571

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Human Tissue ◽

Stage Ii ◽

Tissue Kallikrein ◽

Open Label Study ◽

Download Full-text

New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study

BMC Nephrology ◽

10.1186/s12882-020-01971-x ◽

2020 ◽

Vol 21 (1) ◽

Author(s):

Seok-hyung Kim ◽

Jong Hyun Jhee ◽

Hoon Young Choi ◽

Sang-Ho Lee ◽

Sug Kyun Shin ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Carbon Adsorbent ◽

Indoxyl Sulfate ◽

Advanced Chronic Kidney Disease ◽

Open Label Study ◽

Label Study ◽

Spherical Carbon

Download Full-text

55: A Randomized, Parallel, Open-Label Study to Compare Sevelamer Carbonate Powder Dosed Once Per Day With Sevelamer Hydrochloride Tablets Dosed Three Times Per Day in Chronic Kidney Disease Patients on Hemodialysis

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2009.01.076 ◽

2009 ◽

Vol 53 (4) ◽

pp. B36

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Open Label Study ◽

Label Study ◽

Sevelamer Hydrochloride ◽

Sevelamer Carbonate

Download Full-text

An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis

Journal of Internal Medicine ◽

10.1111/j.1365-2796.2006.01723.x ◽

2006 ◽

Vol 260 (6) ◽

pp. 577-585 ◽

Author(s):

A. K. AGARWAL ◽

M. R. SILVER ◽

J. E. REED ◽

R. K. DHINGRA ◽

W. LIU ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Darbepoetin Alfa ◽

Open Label Study ◽

Download Full-text

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study

Therapeutic Apheresis and Dialysis ◽

10.1111/1744-9987.12888 ◽

2019 ◽

Vol 24 (2) ◽

pp. 115-125 ◽

Author(s):

Tadao Akizawa ◽

Tetsuro Otsuka ◽

Michael Reusch ◽

Mai Ueno

Keyword(s):

Chronic Kidney Disease ◽

Peritoneal Dialysis ◽

Kidney Disease ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Download Full-text

Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study

Clinical and Experimental Nephrology ◽

10.1007/s10157-014-1044-4 ◽

2014 ◽

Vol 19 (4) ◽

pp. 631-638 ◽

Author(s):

Kotaro Soji ◽

Shigehiro Doi ◽

Ayumu Nakashima ◽

Kensuke Sasaki ◽

Toru Kawai ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Angiotensin Ii ◽

Kidney Disease ◽

Receptor Blocker ◽

Angiotensin Ii Receptor Blocker ◽

Advanced Stage ◽

Angiotensin Ii Receptor ◽

Open Label Study ◽

Download Full-text

One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease

Journal of Nephrology ◽

10.5301/jn.2011.6383 ◽

2011 ◽

Vol 24 (6) ◽

pp. 756-763 ◽

Author(s):

Yasuhiko Tomino ◽

Yoshio Shimizu ◽

Chieko Hamada ◽

Atsushi Kurusu ◽

Isao Ohsawa ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Elderly Patients ◽

Open Label Study ◽

Label Study ◽

Antiproteinuric Effect ◽

Download Full-text